Onconova Therapeutics Announces Participation at Upcoming Virtual Events

Rhea-AI Summary

Onconova Therapeutics, Inc. (NASDAQ: ONTX), focused on cancer treatment, announced participation in key upcoming events. The company will engage in the Marcus Evans Healthcare Investment Webinar on September 10, discussing ESG investment opportunities amidst COVID-19. They will also present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 and at the 2nd Annual RAS-Targeted Drug Development Conference on September 16, showcasing their research on rigosertib, a unique RAS antagonist. For additional details, visit onconova.com.

NEWTOWN, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company plans to participate in several upcoming events:

• Marcus Evans Healthcare Investment Webinar
  • Participation on panel titled “Exploring ESG Investment Opportunities in Healthcare amidst COVID-19” on Thursday, September 10 at 1:00 PM ET
     
• H.C. Wainwright 22^nd Annual Global Investment Conference
  • Company presentation on Monday, September 14 at 1:30 PM ET
  • Webcast information: https://wsw.com/webcast/hcw7/ontx/1639361
     
• 2^nd Annual RAS-Targeted Drug Development Conference
  • Company presentation titled “Rigosertib as a Unique Small Molecule RAS Antagonist: Scientific & Clinical Studies” on Wednesday, September 16 at 11:30 AM ET and panel discussion at 12:50 PM ET

About Onconova Therapeutics, Inc.
Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. Using a proprietary chemistry platform, the Company has created a pipeline of targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s RAS pathway inhibitor, oral rigosertib, is currently in a Phase 1/2 investigator-initiated study (IIS) targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Preclinical work with rigosertib in COVID-19 is underway as well. Onconova is in preclinical development with its novel, proprietary, CDK4/6 + ARK5 inhibitor, ON 123300.

For more information, please visit https://www.onconova.com.

Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. These statements relate to Onconova expectations regarding its clinical development plans and patents. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Onconova's clinical trials and regulatory approval of protocols, Onconova’s ability to continue as a going concern, the need for additional financing, our collaborations including the effective termination of the HanX license and securities purchase agreements and plans for partnering certain territories, and those discussed under the heading "Risk Factors" in Onconova's most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q. Any forward-looking statements contained in this release speak only as of its date. Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Press release contact information

Company Contact:

Avi Oler
Onconova Therapeutics, Inc.
267-759-3680
ir@onconova.us
https://www.onconova.com/contact/

Media
David Schull, Russo Partners LLC: (212) 845-4271
Nic Johnson, Russo Partners LLC: (212) 845-4242

 

FAQ

What events is Onconova Therapeutics participating in September 2020?

Onconova Therapeutics will participate in the Marcus Evans Healthcare Investment Webinar on September 10, the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, and the 2nd Annual RAS-Targeted Drug Development Conference on September 16.

What is Onconova Therapeutics presenting at the H.C. Wainwright Conference?

Onconova Therapeutics will give a company presentation on September 14 at 1:30 PM ET during the H.C. Wainwright 22nd Annual Global Investment Conference.

What is the focus of Onconova's presentation at the RAS-Targeted Drug Development Conference?

Onconova's presentation at the RAS-Targeted Drug Development Conference will cover their research titled 'Rigosertib as a Unique Small Molecule RAS Antagonist: Scientific & Clinical Studies' on September 16.

How is Onconova Therapeutics addressing COVID-19?

Onconova Therapeutics is conducting preclinical work with rigosertib to explore its potential in treating COVID-19.

Where can I find more information about Onconova Therapeutics?

More information about Onconova Therapeutics can be found on their official website at onconova.com.